Quality Of Life of Palliative Chemotherapy Naive Patients with Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction Treated with Irinotecan Combined with 5-Fluorouracil And Folinic Acid: Results of A Randomised Phase Iii Trial
![](/themes/Mirage2//images/mime2.png)
Date
2009Author
Curran, Desmond
Pozzo, Carmelo
Zaluski, Jerzy
Dank, Magdalena
Barone, Carlo
Valvere, Vahur
Yalcin, Suayib
Peschel, Christian
Wenczl, Miklós
Goker, Erdem
Bugat, Roland
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Purpose The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented. Methods Patients with measurable or evaluable advanced gastric cancer received IF weekly for 6/7 weeks or CF q4 weeks. QL was assessed using the EORTC QLQ-C30 at baseline, subsequently every 8 weeks until progression and thereafter every 3 months until death. The QL data were analysed using several statistical methods including summary measures and pattern-mixture modelling. Results A total of 333 patients were randomised and treated (IF 170, CF 163). The time-to-progression for IF and CF was 5.0 and 4.2 months (P = 0.088), respectively. The overall compliance rates for QL questionnaire completion were 60 and 56% in the IF and CF arms, respectively. Significant treatment differences were observed for the physical functioning scale (P = 0.024), nausea\vomiting (P = 0.001) and EQ-5D thermometer (P = 0.020) in favour of the IF treatment arm. Conclusion There was a trend in favour of IF over CF in time-to-progression. The IF group also demonstrated a better safety profile than CF and a better QL on a number of multi-item scales, suggesting that IF offers an alternative first-line platinum-free treatment option for advanced gastric cancer.
URI
https://doi.org/10.1007/s11136-009-9493-zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724642/
http://hdl.handle.net/11655/15301